Probiodrug AG 11.11.2014 13:10 Dissemination of a Voting Rights Announcement, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Probiodrug AG Halle (Saale), Germany Handelsregister: Amtsgericht Stendal, HRB 213719 (Commercial Register: Local Court of Stendal, HRB 213719) ISIN: DE0007921835 Publication pursuant to sec. 26 para 1 WpHG (Wertpapierhandelsgesetz - German Securities Trading Act) 1. Publication of notifications of voting rights pursuant to sec. 21 para. 1a WpHG (Wertpapierhandelsgesetz - German Securities Trading Act) 1.1 CFH Beteiligungsgesellschaft mbH, Leipzig, Germany, informed our company pursuant to sec. 21 para. 1a WpHG (German Securities Trading Act) on October 30, 2014, that its voting rights proportion in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, amounted to 4.47% (corresponding to 234,239 voting rights) on October 27, 2014. 0.75% of the voting rights (corresponding to 39,204 voting rights) are to be attributed to CFH Beteiligungsgesellschaft mbH pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. 1.2 Süd Beteiligungen GmbH, Stuttgart, Germany, informed our company pursuant to sec. 21 para. 1a WpHG (German Securities Trading Act) on October 30, 2014, that its voting rights proportion in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, amounted to 4.47% (corresponding to 234,239 voting rights) on October 27, 2014. 4.47% of the voting rights (corresponding to 234,239 voting rights) are to be attributed to Süd Beteiligungen GmbH pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. The voting rights that are to be attributed to Süd Beteiligungen GmbH are held via the following controlled company whose holdings of voting rights amount to 3% or more in Probiodrug AG: CFH Beteiligungsgesellschaft mbH. 1.3 Landesbank Baden-Württemberg, Stuttgart, Germany, informed our company pursuant to sec. 21 para. 1a WpHG (German Securities Trading Act) on October 30, 2014, that its voting rights proportion in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, amounted to 4.47% (corresponding to 234,239 voting rights) on October 27, 2014. 4.47% of the voting rights (corresponding to 234,239 voting rights) are to be attributed to Landesbank Baden-Württemberg pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. The voting rights that are to be attributed to Landesbank Baden-Württemberg are held via the following controlled companies whose holdings of voting rights amount to 3% or more in Probiodrug AG: Süd Beteiligungen GmbH, CFH Beteiligungsbesellschaft mbH. 2. Publication of notifications of voting rights pursuant to sec. 25 WpHG (Wertpapierhandelsgesetz - German Securities Trading Act) 2.1 Biotech Growth N.V., Willemstad, Curacao, the Netherlands Antilles (Dutch Caribbean), informed our company pursuant to sec. 25 WpHG (German Securities Trading Act) on November 5, 2014 as follows: Issuer: Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany Notifier: Biotech Growth N.V., Willemstad, Curacao, the Netherlands Antilles (Dutch Caribbean) Triggering Event: Exceeding threshold Threshold(s) exceeded: 5%, 10% and 15% Date at which the threshold is exceeded: October 29, 2014 Voting rights proportion: 15.66% (corresponding to 1,051,734 voting rights) Detailed information on the voting rights proportion: - Financial/other instruments pursuant to Sec. 25 WpHG: 0.23% (corresponding to 15,115 voting rights) - Thereof held indirectly: 0.00% (corresponding to 0 voting rights) - Voting rights pursuant to sec. 21, 22 WpHG: 15.43% (corresponding to 1,036,619 voting rights) 2.2 BB Biotech AG, Schaffhausen, Switzerland, informed our company pursuant to sec. 25 WpHG (German Securities Trading Act) on November 5, 2014 as follows: Issuer: Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany Notifier: BB Biotech AG, Schaffhausen, Switzerland, Triggering Event: Exceeding threshold Threshold(s) exceeded: 5%, 10% and 15% Date at which the threshold is exceeded: October 29, 2014 Voting rights proportion: 15.66% (corresponding to 1,051,734 voting rights) Detailed information on the voting rights proportion: - Financial/other instruments pursuant to Sec. 25 WpHG: 0.23% (corresponding to 15,115 voting rights) - Thereof held indirectly: 0.23% (corresponding to 15,115 voting rights) - Voting rights pursuant to sec. 21, 22 WpHG: 15.43% (corresponding to 1,036,619 voting rights) Detailed information on financial/other instruments pursuant to sec. 25 WpHG: - Chain of controlled undertakings: Biotech Growth N.V. 2.3 HBM Healthcare Investments (Cayman) Ltd, George Town, Grand Cayman, Cayman Islands, informed our company pursuant to sec. 25 WpHG (German Securities Trading Act) on November 5, 2014 as follows: Issuer: Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany Notifier: HBM Healthcare Investments (Cayman) Ltd, George Town, Grand Cayman, Cayman Islands Triggering Event: Exceeding threshold Threshold(s) exceeded: 5% and 10% Date at which the threshold is exceeded: October 29, 2014 Voting rights proportion: 11.42% (corresponding to 766,956 voting rights) Detailed information on the voting rights proportion: - Financial/other instruments pursuant to Sec. 25 WpHG: 0.14% (corresponding to 9,474 voting rights) - Thereof held indirectly: 0.00% (corresponding to 0 voting rights) - Voting rights pursuant to sec. 21, 22 WpHG: 11.28% (corresponding to 757,482 voting rights) 2.4 HBM Healthcare Investments AG, Zug, Schweiz, informed our company pursuant to sec. 25 WpHG (German Securities Trading Act) on November 5, 2014 as follows: Issuer: Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany Notifier: HBM Healthcare Investments AG, Zug, Schweiz Triggering Event: Exceeding threshold Threshold(s) exceeded: 5% and 10% Date at which the threshold is exceeded: October 29, 2014 Voting rights proportion: 11.42% (corresponding to 766,956 voting rights) Detailed information on the voting rights proportion: - Financial/other instruments pursuant to Sec. 25 WpHG: 0.14% (corresponding to 9,474 voting rights) - Thereof held indirectly: 0.14% (corresponding to 9,474 voting rights) - Voting rights pursuant to sec. 21, 22 WpHG: 11.28% (corresponding to 757,482 voting rights) Detailed information on financial/other instruments pursuant to sec. 25 WpHG: - Chain of controlled undertakings: HBM Healthcare Investments (Cayman) Ltd 2.5 Coöperatief LSP IV U.A., Amsterdam, the Netherlands, informed our company pursuant to sec. 25 WpHG (German Securities Trading Act) on November 5, 2014 as follows: Issuer: Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany Notifier: Coöperatief LSP IV U.A., Amsterdam, the Netherlands Triggering Event: Exceeding threshold Threshold(s) exceeded: 5% Date at which the threshold is exceeded: October 29, 2014 Voting rights proportion: 8.69% (corresponding to 583,789 voting rights) Detailed information on the voting rights proportion: - Financial/other instruments pursuant to Sec. 25 WpHG: 0.13% (corresponding to 8,478 voting rights) - Thereof held indirectly: 0.00% (corresponding to 0 voting rights) - Voting rights pursuant to sec. 21, 22 WpHG: 8.56% (corresponding to 575,311 voting rights) - Publication of notifications of voting rights pursuant to sec. 21 para. 1 WpHG (Wertpapierhandelsgesetz - German Securities Trading Act) 3.1 JPMorgan Asset Management (UK) Limited, London, United Kingdom, informed our company pursuant to sec. 21 para. 1 WpHG (German Securities Trading Act) on October 31, 2014, that its voting rights proportion exceeded the threshold of 3% of the voting rights in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, on October 31, 2014, and that its voting rights proportion in Probiodrug AG amounted to 3.87% (corresponding to 260,000 voting rights). 3.87% (corresponding to 260,000 voting rights) are to be attributed to JPMorgan Asset Management (UK) Limited pursuant to sec. 22 para. 1 sentence 1 no. 6 WpHG. 3.2 HBM Healthcare Investments (Cayman) Ltd, George Town, Grand Cayman, Cayman Islands, informed our company pursuant to sec. 21 para. 1 WpHG (German Securities Trading Act) on November 5, 2014, that its voting rights proportion exceeded the threshold of 10% of the voting rights in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, on October 29, 2014, and that its voting rights proportion in Probiodrug AG amounted to 11.28% (corresponding to 757,482 voting rights) on that date. 3.3 HBM Healthcare Investments AG, Zug, Switzerland, informed our company pursuant to sec. 21 para. 1 WpHG (German Securities Trading Act) on November 5, 2014, that its voting rights proportion exceeded the threshold of 10% of the voting rights in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, on October 29, 2014, and that its voting rights proportion in Probiodrug AG amounted to 11.28% (corresponding to 757,482 voting rights) on that date. 11.28% (corresponding to 757,482 voting rights) are to be attributed to HBM Healthcare Investments AG pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. The voting rights that are to be attributed to HBM Healthcare Investments AG are held via the following controlled companies whose holdings of voting rights amount to 3% or more in Probiodrug AG: HBM Healthcare Investments (Cayman) Ltd.. 3.4 Edmond de Rothschild Investment Partners, Paris, France, informed our company pursuant to sec. 21 para. 1 WpHG (German Securities Trading Act) on November 6, 2014, that its voting rights proportion fell below the threshold of 15% of the voting rights in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, on October 29, 2014, and that its voting rights proportion in Probiodrug AG amounted to 14.43% (corresponding to 969,613 voting rights) on that date. 14.43% (corresponding to 969,613 voting rights) are to be attributed to Edmond de Rothschild Investment Partners pursuant to sec. 22 para. 1 sentence 1 no. 6 WpHG. 3.5 IBG Beteiligungsverwaltung Komplementär GmbH, Magdeburg, Germany, informed our company pursuant to sec. 21 para. 1 WpHG (German Securities Trading Act) on November 5, 2014, that its voting rights proportion fell below the threshold of 15% of the voting rights in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, on October 29, 2014, and that its voting rights proportion in Probiodrug AG amounted to 13.64% (corresponding to 916,435 voting rights) on that date. 13.64% (corresponding to 916,435 voting rights) are to be attributed to IBG Beteiligungsverwaltung Komplementär GmbH pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. The voting rights that are to be attributed to IBG Beteiligungsverwaltung Komplementär GmbH are held via the following controlled companies whose holdings of voting rights amount to 3% or more in Probiodrug AG: IBG Risikokapitalfonds I GmbH & Co. KG, IBG Risikokapitalfonds II GmbH & Co. KG. 3.6 IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, Magdeburg, Germany, informed our company pursuant to sec. 21 para. 1 WpHG (German Securities Trading Act) on November 5, 2014, that its voting rights proportion fell below the threshold of 15% of the voting rights in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, on October 29, 2014, and that its voting rights proportion in Probiodrug AG amounted to 14.14% (corresponding to 949,607 voting rights) on that date. 13.64% (corresponding to 916,435 voting rights) are to be attributed to IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. The voting rights that are to be attributed to IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH are held via the following controlled companies whose holdings of voting rights amount to 3% or more in Probiodrug AG: IBG Beteiligungsverwaltung Komplementär GmbH, IBG Risikokapitalfonds I GmbH & Co. KG, IBG Risikokapitalfonds II GmbH & Co. KG. 3.7 Sachsen-Anhalt, Land - Ministerium der Finanzen des Landes Sachsen-Anhalt, Magdeburg, Germany, informed our company pursuant to sec. 21 para. 1 WpHG (German Securities Trading Act) on November 5, 2014, that its voting rights proportion fell below the threshold of 15% of the voting rights in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, on October 29, 2014, and that its voting rights proportion in Probiodrug AG amounted to 14.14% (corresponding to 949,607 voting rights) on that date. 14.14% (corresponding to 949,607 voting rights) are to be attributed to Sachsen-Anhalt, Land, pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. The voting rights that are to be attributed to Sachsen-Anhalt, Land, are held via the following controlled companies whose holdings of voting rights amount to 3% or more in Probiodrug AG: IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, IBG Beteiligungsverwaltung Komplementär GmbH, IBG Risikokapitalfonds I GmbH & Co. KG, IBG Risikokapitalfonds II GmbH & Co. KG. 3.8 Kempen & Co. N.V., Amsterdam, the Netherlands, informed our company pursuant to sec. 21 para. 1 WpHG (German Securities Trading Act) on November 4, 2014, that its voting rights proportion exceeded the thresholds of 3 and 5% of the voting rights in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, on October 29, 2014, and that its voting rights proportion in Probiodrug AG amounted to 8.46% (corresponding to 568,390 voting rights) on that date. 3.9 F. van Lanschot Bankiers N.V., 52 JN, 's-Hertogenbosch, the Netherlands, informed our company pursuant to sec. 21 para. 1 WpHG (German Securities Trading Act) on November 4, 2014, that its voting rights proportion exceeded the thresholds of 3 and 5% of the voting rights in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, on October 29, 2014, and that its voting rights proportion in Probiodrug AG amounted to 8.46% (corresponding to 568,390 voting rights) on that date. 8.46% (corresponding to 568,390 voting rights) are to be attributed to F. van Lanschot Bankiers N.V. pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. The voting rights that are to be attributed to F. van Lanschot Bankiers N.V. are held via the following controlled companies whose holdings of voting rights amount to 3% or more in Probiodrug AG: Kempen & Co. N.V.. 3.10 Van Lanschot N.V., 52 JN, 's-Hertogenbosch, the Netherlands, informed our company pursuant to sec. 21 para. 1 WpHG (German Securities Trading Act) on November 5, 2014, that its voting rights proportion exceeded the thresholds of 3 and 5% of the voting rights in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, on October 29, 2014, and that its voting rights proportion in Probiodrug AG amounted to 8.46% (corresponding to 568,390 voting rights) on that date. 8.46% (corresponding to 568,390 voting rights) are to be attributed to Van Lanschot N.V. pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. The voting rights that are to be attributed to Van Lanschot N.V. are held via the following controlled companies whose holdings of voting rights amount to 3% or more in Probiodrug AG: F. van Lanschot Bankiers N.V., Kempen & Co. N.V.. 3.11 Kempen & Co. N.V., Amsterdam, the Netherlands, informed our company pursuant to sec. 21 para. 1 WpHG (German Securities Trading Act) on November 4, 2014, that its voting rights proportion fell below the threshold of 5% of the voting rights in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, on October 31, 2014, and that its voting rights proportion in Probiodrug AG amounted to 4.93% (corresponding to 330,802 voting rights) on that date. 3.12 F. van Lanschot Bankiers N.V., 52 JN, 's-Hertogenbosch, the Netherlands, informed our company pursuant to sec. 21 para. 1 WpHG (German Securities Trading Act) on November 4, 2014, that its voting rights proportion fell below the threshold of 5% of the voting rights in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, on October 31, 2014, and that its voting rights proportion in Probiodrug AG amounted to 4.93% (corresponding to 330,802 voting rights) on that date. 4.93% (corresponding to 330,802 voting rights) are to be attributed to F. van Lanschot Bankiers N.V. pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. The voting rights that are to be attributed to F. van Lanschot Bankiers N.V. are held via the following controlled companies whose holdings of voting rights amount to 3% or more in Probiodrug AG: Kempen & Co. N.V.. 3.13 Van Lanschot N.V., 52 JN, 's-Hertogenbosch, the Netherlands, informed our company pursuant to sec. 21 para. 1 WpHG (German Securities Trading Act) on November 5, 2014, that its voting rights proportion fell below the threshold of 5% of the voting rights in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, on October 31, 2014, and that its voting rights proportion in Probiodrug AG amounted to 4.93% (corresponding to 330,802 voting rights) on that date. 4.93% (corresponding to 330,802 voting rights) are to be attributed to Van Lanschot N.V. pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. The voting rights that are to be attributed to Van Lanschot N.V. are held via the following controlled companies whose holdings of voting rights amount to 3% or more in Probiodrug AG: F. van Lanschot Bankiers N.V., Kempen & Co. N.V.. 3.14 Kempen & Co. N.V., Amsterdam, the Netherlands, informed our company pursuant to sec. 21 para. 1 WpHG (German Securities Trading Act) on November 11, 2014, that its voting rights proportion fell below the threshold of 3% of the voting rights in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, on November 3, 2014, and that its voting rights proportion in Probiodrug AG amounted to 0.96% (corresponding to 64,245 voting rights) on that date. 3.15 F. van Lanschot Bankiers N.V., 52 JN, 's-Hertogenbosch, the Netherlands, informed our company pursuant to sec. 21 para. 1 WpHG (German Securities Trading Act) on November 11, 2014, that its voting rights proportion fell below the threshold of 3% of the voting rights in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, on November 3, 2014, and that its voting rights proportion in Probiodrug AG amounted to 0.96% (corresponding to 64,425 voting rights) on that date. 0.96% (corresponding to 64,425 voting rights) are to be attributed to F. van Lanschot Bankiers N.V. pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. 3.16 Van Lanschot N.V., 52 JN, 's-Hertogenbosch, the Netherlands, informed our company pursuant to sec. 21 para. 1 WpHG (German Securities Trading Act) on November 11, 2014, that its voting rights proportion fell below the threshold of 3% of the voting rights in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, on November 3, 2014, and that its voting rights proportion in Probiodrug AG amounted to 0.96% (corresponding to 64,425 voting rights) on that date. 0.96% (corresponding to 64,425 voting rights) are to be attributed to Van Lanschot N.V. pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. 3.17 Wellington Hedge Management, LLC, Boston, Massachusetts, USA, informed our company pursuant to sec. 21 para. 1 WpHG (German Securities Trading Act) on November 11, 2014, that its voting rights proportion fell below the threshold of 3% of the voting rights in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, on October 29, 2014, and that its voting rights proportion in Probiodrug AG amounted to 2.38% (corresponding to 160,049 voting rights) on that date. 2.38% (corresponding to 160,049 voting rights) are to be attributed to Wellington Hedge Management, LLC, pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. - Publication of notifications of voting rights pursuant to sec. 21 para. 1a WpHG (Wertpapierhandelsgesetz - German Securities Trading Act) - Correction of releases dated November 7, 2014 4.1 LSP IV Management B.V., Amsterdam, Netherlands, informed our company pursuant to sec. 21 para. 1a WpHG (German Securities Trading Act) on November 3, 2014, that its voting rights proportion in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, amounted to 8.45% on October 27, 2014 (corresponding to 442.806 voting rights). 8.45% of the voting rights (corresponding to 442.806 voting rights) are to be attributed to LSP IV Management B.V. pursuant to sec. 22 para. 1 sentence 1 no. 6 WpHG. The voting rights that are to be attributed to LSP IV Management B.V. are held via the following company whose holdings of voting rights amount to 3% or more in Probiodrug AG: Coöperatief LSP IV U.A. 4.2 LSP Management Group B.V., Amsterdam, Netherlands, informed our company pursuant to sec. 21 para. 1a WpHG (German Securities Trading Act) on November 4, 2014, that its voting rights proportion in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, amounted to 8.45% on October 27, 2014 (corresponding to 442.806 voting rights). 8.45% of the voting rights (corresponding to 442.806 voting rights) are to be attributed to LSP Management Group B.V. pursuant to sec. 22 para. 1 sentence 1 no. 6 and sentence 2 WpHG. The voting rights that are to be attributed to LSP Management Group B.V. are held via the following company whose holdings of voting rights amount to 3% or more in Probiodrug AG: Coöperatief LSP IV U.A. 4.3 BB Biotech AG, Schaffhausen, Switzerland, informed our company pursuant to sec. 21 para. 1a WpHG (German Securities Trading Act) on November 3, 2014, that its voting rights proportion in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, amounted to 15.06% on October 27, 2014 (corresponding to 789,439 voting rights). 15.06% of the voting rights (corresponding to 789,439 voting rights) are to be attributed to BB Biotech AG pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. The voting rights that are to be attributed to BB Biotech AG are held via the following controlled company whose holdings of voting rights amount to 3% or more in Probiodrug AG: Biotech Growth N.V. 4.4 HBM Healthcare Investments AG, Zug, Switzerland, informed our company pursuant to sec. 21 para. 1a WpHG (German Securities Trading Act) on October 31, 2014, that its voting rights proportion in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, amounted to 9.44% on October 27, 2014 (corresponding to 494,825 voting rights). 9.44% of the voting rights (corresponding to 494,825 voting rights) are to be attributed to HBM Healthcare Investments AG pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. The voting rights that are to be attributed to HBM Healthcare Investments AG are held via the following controlled company whose holdings of voting rights amount to 3% or more in Probiodrug AG: HBM Healthcare Investments (Cayman) Ltd. 4.5 Edmond de Rothschild Investment Partners, Paris, France, informed our company pursuant to sec. 21 para. 1a WpHG (German Securities Trading Act) on November 6, 2014, that its voting rights proportion in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, amounted to 15.67% on October 27, 2014 (corresponding to 821,409 voting rights). 15.67% of the voting rights (corresponding to 821,409 voting rights) are to be attributed to Edmond de Rothschild Investment Partners pursuant to sec. 22 para. 1 sentence 1 no. 6 WpHG. 4.6 IBG Beteiligungsverwaltung Komplementär GmbH, Magdeburg, Germany, informed our company pursuant to sec. 21 para. 1a WpHG (German Securities Trading Act) on October 31, 2014, that its voting rights proportion in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, amounted to 17.48% on October 27, 2014 (corresponding to 916,435 voting rights). 17.48% of the voting rights (corresponding to 916,435 voting rights) are to be attributed to IBG Beteiligungsverwaltung Komplementär GmbH pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. The voting rights that are to be attributed to IBG Beteiligungsverwaltung Komplementär GmbH are held via the following controlled companies whose holdings of voting rights amount to 3% or more in Probiodrug AG: IBG Risikokapitalfonds I GmbH & Co. KG, IBG Risikokapitalfonds II GmbH & Co. KG. 4.7 IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, Magdeburg, Germany, informed our company pursuant to sec. 21 para. 1a WpHG (German Securities Trading Act) on October 31, 2014, that its voting rights proportion in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, amounted to 18.12% on October 27, 2014 (corresponding to 949,607 voting rights). 17.48% of the voting rights (corresponding to 916,435 voting rights) are to be attributed to IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. The voting rights that are to be attributed to IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH are held via the following controlled companies whose holdings of voting rights amount to 3% or more in Probiodrug AG: IBG Beteiligungsverwaltung Komplementär GmbH, IBG Risikokapitalfonds I GmbH & Co. KG, IBG Risikokapitalfonds II GmbH & Co. KG. 4.8 Sachsen-Anhalt, Land - Ministerium der Finanzen des Landes Sachsen-Anhalt, Magdeburg, Germany, informed our company pursuant to sec. 21 para. 1a WpHG (German Securities Trading Act) on October 31, 2014, that its voting rights proportion in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, amounted to 18.12% on October 27, 2014 (corresponding to 949,607 voting rights). 18.12% of the voting rights (corresponding to 949,607 voting rights) are to be attributed to Sachsen-Anhalt, Land - Ministerium der Finanzen des Landes Sachsen-Anhalt, pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. The voting rights that are to be attributed to Sachsen-Anhalt, Land - Ministerium der Finanzen des Landes Sachsen-Anhalt, are held via the following controlled companies whose holdings of voting rights amount to 3% or more in Probiodrug AG: IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, IBG Beteiligungsverwaltung Komplementär GmbH, IBG Risikokapitalfonds I GmbH & Co. KG, IBG Risikokapitalfonds II GmbH & Co. KG, 4.9 Biogen Idec Inc., Cambridge, Massachusetts, USA, informed our company pursuant to sec. 21 para. 1a WpHG (German Securities Trading Act) on October 30, 2014, that its voting rights proportion in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, amounted to 4.04% on October 27, 2014 (corresponding to 211,651 voting rights). 4.04% of the voting rights (corresponding to 211,651 voting rights) are to be attributed to Biogen Idec Inc. pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. The voting rights that are to be attributed to Biogen Idec Inc. are held via the following controlled company whose holdings of voting rights amount to 3% or more in Probiodrug AG: Biogen Idec MA Inc. 4.10 TVM V Life Science Management GmbH & Co. KG, Munich, Germany, informed our company pursuant to sec. 21 para. 1a WpHG (German Securities Trading Act) on October 31, 2014, that its voting rights proportion in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, amounted to 9.53% on October 27, 2014 (corresponding to 499,368 voting rights). 9.53% of the voting rights (corresponding to 499,368 voting rights) are to be attributed to TVM V Life Science Management GmbH & Co. KG pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. The voting rights that are to be attributed to TVM V Life Science Management GmbH & Co. KG are held via the following controlled company whose holdings of voting rights amount to 3% or more in Probiodrug AG: TVM V Life Science Ventures GmbH & Co. KG. 4.11 Wellington Hedge Management, LLC, Boston, Massachusetts, USA, informed our company pursuant to sec. 21 para. 1a WpHG (German Securities Trading Act) on November 6, 2014, that its voting rights proportion in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, amounted to 3.05% on October 27, 2014 (corresponding to 160,049 voting rights). 3.05% of the voting rights (corresponding to 160,049 voting rights) are to be attributed to Wellington Hedge Management, LLC pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG. 4.12 Wellington Management Company, LLP, Boston, Massachusetts, USA, informed our company pursuant to sec. 21 para. 1a WpHG (German Securities Trading Act) on November 6, 2014, that its voting rights proportion in Probiodrug AG, Weinbergweg 22, 06120 Halle (Saale), Germany, ISIN DE0007921835, amounted to 4.06% on October 27, 2014 (corresponding to 212,771 voting rights). 4.06% of the voting rights (corresponding to 212,771 voting rights) are to be attributed to Wellington Management Company, LLP, pursuant to sec. 22 para. 1 sentence 1 no. 1 WpHG, and also concurrently pursuant to sec. 22 para. 1 sentence 1 no. 6 WpHG. The voting rights that are to be attributed to Wellington Management Company, LLP are held via the following controlled company whose holdings of voting rights amount to 3% or more in Probiodrug AG: Wellington Hedge Management, LLC. Halle (Saale), in November 2014 The Management 11.11.2014 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Probiodrug AG Weinbergweg 22 06120 Halle/Saale Germany Internet: www.probiodrug.de End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-PVR: Probiodrug AG: Release according to Article 26,
Top 10 Most Recent News Articles
DigiKey’s Arduino Webinar Puts Edge AI Hardware to Work
A Small Board With a Big Practical Question Edge AI is finally getting dragged out of the slide deck and onto the workbench, which is where it ought to prove itself. DigiKey plans to host a free 60-minute webinar on Dec. 2, 2026, at 10 a.m. CST covering Arduino’s new VENTUNO Q edge AI computer. The session promises a hardware tour, an Arduino App Lab walkthrough, and a...
Continue Reading
Cold-Season Cleaning Advice Has a Practical Catch!
Remote Controls Are Nobody’s First Suspect A television remote can make the rounds all evening and never see a cloth, which is precisely why Maid Brigade’s cold-and-flu-season reminder lands as common sense rather than revelation. The Scottsdale cleaning company is telling households to look past the usual kitchen counter and bathroom sink routine. Fair enough. People...
Continue Reading
Kawneer’s OptiQ Window Wins a Useful Design Signal
Three Nods, One Very Practical Product Claim Windows rarely stir much excitement outside an architect’s specification binder, but Kawneer has put together a respectable run with its OptiQ Offset Fixed/Projected Series Window. On November 18, 2026, the architectural aluminum-systems maker said the product had won in the Windows and Doors category at both the 2026...
Continue Reading
Another Nine's A9OS Puts Software at Center of Golf
A golf simulator chain is trying to turn the boring plumbing into its sharpest club. Another Nine’s A9OS is not merely a booking widget dressed up for a franchise brochure; it is meant to run the whole 24/7 operation, from payments and door access to cameras, simulator support and guest help. That ambition deserves attention because this is exactly where a staff-free...
Continue Reading
Novo and nference Push Whole-Body Data Into Research
Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...
Continue Reading
AWK Adds Fayette Water System With $9M Upgrade Plan
Small water systems do not usually collapse in one dramatic heap; they get worn down by scattered pipes, compliance demands, thin staffing and bills nobody wants to raise. That is the backdrop for Pennsylvania American Water’s completed $32.8 million purchase of the Indian Creek Valley Water Authority system. For American Water shareholders, this is the familiar...
Continue Reading
CATL Makes Its APEC Case Beyond the Electric Car Market
A 99-Second Pitch With Bigger Ambitions Battery swapping got a rare moment in the geopolitical sunlight at Shenzhen's APEC CEO Summit, and CATL was plainly trying to make that moment count. Dr. Robin Zeng, the company's founder, chairman and chief executive, used the opening business dialogue to argue that the Asia-Pacific region holds more opportunity than trouble. Fair...
Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector
Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...
Continue Reading
Three Deal Reviews Put Merger Terms Under Scrutiny
Three proposed transactions just picked up the sort of legal glare boards hate seeing. A shareholder-rights firm, Halper Sadeh, said on November 18, 2026 that it is investigating whether the deals involving Greenland Energy, Rapid Micro Biosystems and Aytu BioPharma may involve federal securities-law violations or breaches of fiduciary duty. That is an allegation worth...
Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing
Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...
Continue ReadingTop 5 Most Recently Viewed Articles
Big Lots Adjusts Strategy Amid Bankruptcy Process Challenges
Big Lots Updates on Court-Supervised Process No Longer Anticipates Closing Previously Announced Sale to Nexus Capital Management Continues Efforts Towards a Going Concern Transaction Gearing Up for Going Out of Business Sales at Remaining Locations Big Lots, Inc. has recently made crucial updates regarding its financial restructuring efforts. The company has announced...
Continue Reading
Detailed Overview of Man Group PLC's Stake in American Axle
Key Information About Man Group PLC's Disclosures FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE This document represents a disclosure by a person with interests in relevant securities, specifically when owning 1% or more of American Axle & Manufacturing Holdings, Inc. As per Rule 8.3 of the Takeover Code, certain details regarding the interests and...
Continue Reading
Westlake Chemical Gets Boost from Analysts with New Targets
Westlake Chemical Upgraded to Neutral Recently, BofA Securities made a notable adjustment regarding Westlake Chemical (NASDAQ: WLK), changing the stock's rating from Underperform to Neutral. This upgrade included raising the price target to $159 from $151, reflecting a more balanced view on the company's trajectory. The changes stem from a reassessment that weighs current...
Continue Reading
Envision Energy Recognized Among Leading Climate Tech Innovators
Envision Energy's Recognition in Climate Technology Envision Energy has earned a well-deserved place on a prestigious list recognizing transformative companies in climate technology. This acknowledgment highlights their significant contributions in the fight against climate change through innovative renewable energy solutions. A Global Leader in Renewable Energy Known for...
Continue Reading
Exploring Franco-Nevada's Ten-Year Investment Journey
Understanding Franco-Nevada's Investment Growth Franco-Nevada (NYSE: FNV) has showcased impressive performance over the last decade, delivering an average annual return of 14.64%. With a market capitalization of $30.52 billion, it has consistently outperformed the overall market by 3.21% on an annualized basis. The Impact of Compounding Returns Let's say an investor...
Continue Reading